Tetraphase Pharms Drug Patent Portfolio
Tetraphase Pharms owns 1 orange book drug protected by 4 US patents Given below is the list of Tetraphase Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10961190 | Crystalline forms of eravacycline | 19 Oct, 2037 | Active |
| US11578044 | Crystalline forms of eravacycline | 19 Oct, 2037 | Active |
| US8906887 | C7-fluoro substituted tetracycline compounds | 28 Dec, 2030 | Active |
| US8796245 | C7-fluoro substituted tetracycline compounds | 07 Aug, 2029 | Active |
Latest Legal Activities on Tetraphase Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Tetraphase Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8906887 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US8906887 |
|
Recordation of Patent Grant Mailed
Critical
| 14 Feb, 2023 | US11578044 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 14 Feb, 2023 | US11578044 |
|
Email Notification
Critical
| 26 Jan, 2023 | US11578044 |
|
Issue Notification Mailed
Critical
| 25 Jan, 2023 | US11578044 |
| Dispatch to FDC | 09 Jan, 2023 | US11578044 |
|
Application Is Considered Ready for Issue
Critical
| 09 Jan, 2023 | US11578044 |
| Supplemental Papers - Oath or Declaration | 05 Jan, 2023 | US11578044 |
|
Issue Fee Payment Received
Critical
| 05 Jan, 2023 | US11578044 |
|
Issue Fee Payment Verified
Critical
| 05 Jan, 2023 | US11578044 |
|
Mail Notice of Allowance
Critical
| 06 Oct, 2022 | US11578044 |
|
Email Notification
Critical
| 06 Oct, 2022 | US11578044 |
|
Electronic Review
Critical
| 06 Oct, 2022 | US11578044 |
|
Notice of Allowance Data Verification Completed
Critical
| 03 Oct, 2022 | US11578044 |
Tetraphase Pharms's Family Patents
Tetraphase Pharms Drug List
Given below is the complete list of Tetraphase Pharms's drugs and the patents protecting them.
1. Xerava
Xerava is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10961190 | Crystalline forms of eravacycline |
19 Oct, 2037
(12 years from now)
| Active |
| US11578044 | Crystalline forms of eravacycline |
19 Oct, 2037
(12 years from now)
| Active |
| US8906887 | C7-fluoro substituted tetracycline compounds |
28 Dec, 2030
(5 years from now)
| Active |
| US8796245 | C7-fluoro substituted tetracycline compounds |
07 Aug, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xerava's drug page